These emerging extratumoral tissue biomarkers, including AFP, CRAFITY score, SLFNs, and plasma IL-6, hold promise for improving the prediction of treatment response in HCC patients undergoing immunotherapy. This evidence concerns the gene AFP and hepatocellular carcinoma.